Dzau V J, Mukoyama M, Pratt R E
Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, School of Medicine, Stanford, CA 94305-5246.
J Hypertens Suppl. 1994 Jul;12(2):S1-5.
Angiotensin II receptors: Angiotensin II is a key regulator of cardiovascular homeostasis. At least two distinct angiotensin II receptor subtypes are defined, on the basis of their differential pharmacological and biochemical properties, and designated as type 1 (AT1) and type 2 (AT2) receptors. AT1 subtypes: Recent cloning has revealed that the AT1 type belongs to a seven-transmembrane, G protein-coupled receptor superfamily. The AT1 receptor comprises two isoforms, AT1a and AT1b, which are strikingly similar in amino acid structure, pharmacological specificity and signal transduction mechanism. To date, the evidence indicates that almost all of the known effects of angiotensin II in adult tissues are attributable to the AT1 receptor. AT2 subtype: Much less is known about the function of the AT2 receptor, but its abundant expression in fetal tissues, immature brain, skin wounds, and atretic ovarian follicles suggest that it affects growth and development. The AT2 receptor complementary (c)DNA has recently been cloned. It encodes a 363 amino acid protein with unique tissue distributions and developmental patterns. It is 34% identical in sequence to the AT1 receptor, sharing a seven-transmembrane domain topology.
Further research in defining the functions of the AT1 and AT2 receptor subtypes in cardiovascular regulation will provide new opportunities for new drug discovery and for the characterization of angiotensin II antagonists.
血管紧张素II受体:血管紧张素II是心血管稳态的关键调节因子。根据其不同的药理和生化特性,至少定义了两种不同的血管紧张素II受体亚型,分别命名为1型(AT1)和2型(AT2)受体。
AT1亚型:最近的克隆研究表明,AT1型属于七跨膜、G蛋白偶联受体超家族。AT1受体包含两种亚型,即AT1a和AT1b,它们在氨基酸结构、药理特异性和信号转导机制方面极为相似。迄今为止,有证据表明血管紧张素II在成体组织中的几乎所有已知作用都归因于AT1受体。
AT2亚型:关于AT2受体的功能了解较少,但其在胎儿组织、未成熟脑、皮肤伤口和闭锁卵泡中的大量表达表明它影响生长和发育。AT2受体互补(c)DNA最近已被克隆。它编码一种含有363个氨基酸的蛋白质,具有独特的组织分布和发育模式。其序列与AT1受体有34%的同源性,共享七跨膜结构域拓扑结构。
进一步研究确定AT1和AT2受体亚型在心血管调节中的功能,将为新药研发和血管紧张素II拮抗剂的特性研究提供新的机会。